Randox has developed a rapid test for COVID-19 (SARS-CoV-2), the new strain of coronavirus.
The game-changing Viral Respiratory Tract Infection (VRI) Array is available on The Vivalytic, a molecular point-of-care platform brought to the market by Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions. The revolutionary VRI Array can identify SARS-CoV-2 and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.
Also available is the COVID-19 Array which detects the SARS-CoV-2 virus as well as sarbecovirus (SARS, SARS Like, SARS-CoV-2) ensuring accurate diagnosis. Utilising patented Randox Biochip Technology, 54 patient samples and 540 test results can be processed in less than 5 hours on the Randox Evidence Investigator, a semi-automated analyser.
Solutions for COVID-19 Detection and Monitoring
Randox | COVID-19 Array
The Randox COVID-19 Array targets genes for SARS-CoV-2 and for sarbecovirus (SARS, SARS like, SARS-CoV-2) and are in line with WHO and CDC recommendations. These genes represent conserved regions of the genome and have been chosen due to their sensitivity and specificity
Vivalytic | Viral Respiratory Tract Infections Array (VRI)
|Cat Code||Vivalytic Platform: Cat No: F09G300115 |
VRI Cartridge: (Box of 15 Cartridges)
Cat No: F09G300382
|Sample Type||Nasopharyngeal Swab|
|Sample Volume||Vivalytic: 300µl clinical sample|
(SARS, SARS like, SARS-CoV-2)
|Coronavirus 229E/NL63||Adenovirus A/B/C/D/E||Influenza B|
|Coronavirus OC43/HKUI||Enterovirus A/B/C||Rhinovirus A/B|
|Middle East Respiratory|
Syndrome Coronavirus (MERS-CoV)
Randox | Evidence Investigator
The Evidence Investigator is a compact semi-automated benchtop analyser. It is the perfect fit for medium throughput laboratories seeking maximum use of bench space without compromising on the volume of samples processed.
- Estimated turnaround time of less than 5 hours
- Medium to high throughput (Capable of processing 54 samples and 540 test results in less than 5 hours)
- Detection from nucleic acid
- Batch testing
- Suitable for laboratory setting
- Comprehensive test menu
Randox Laboratories have developed a game-changing point of care coronavirus test. The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.
Vivalytic is a point of care platform designed and engineered by Bosch. The platform is powered by Randox Multiplex Biochip Technology, enabling multiple results from one patient sample. Combining world leading Bosch engineering with innovative Randox molecular tests, provides the healthcare industry with precise diagnostics to implement targeted treatment.
The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR.
Randox | QCMD Coronavirus EQA Scheme
Pilot EQA scheme for Coronaviruses which will include inactivated coronavirus SARS-CoV-2. This panel will consist of 6 whole pathogen panel members which should be analysed for SARS-CoV-2 or other coronaviruses. The panel members containing SARS-CoV-2 are inactivated and not infectious.
All participants of this scheme will receive a “real-time” report on submission of results, followed by a full EQA report with individual laboratory performance.
|Feature | Specification||Available Format(s) | Specifications|
|Total Number of Challenges||1|
|Number of Panel Members||8|
|Distribution / Testing Period||Q2|
|Registration Close Date||17 April 2020|
|Sample NA Target Source||Cultured and/or Clinical Material|
|Matrix Panel Format||Transport Medium|
|Panel Member Target Range||Covering Clinical Range|
|Panel Member Sample Volume||1.0 mL|
|Panel Sample Pre-Treatment Requirement||Ready for analysis. Treat as clinical samples and analyse accordingly|
|Panel Analysis Type||Qualitative|
|Panel Testing||Evaluated by various molecular methodologies|
|Storage / Shipment Conditions|
Randox | Qnostics SARS-CoV-2 Medium Q Control
Randox is pleased to announce the launch of the new Qnostics SARS-CoV-2 Medium Q Control designed to ensure the accuracy and reliability of molecular assays used in the testing of COVID-19.
|Features and Benefits|
|Whole Pathogen||Contains the entire SARS CoV-2 genome and compatible with commercial and in-house assays targeting the CDC and WHO consensus sequences.|
|Full Process Control||Effectively monitor the performance of the entire testing process from extraction to amplification and detection.|
|Highly Characterised||Quantified by digital PCR ensuring batch to batch reproducibility.|
|Third Party||An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.|
|Superior Manufacturing||Manufactured to ISO 13485:2016 standard and traceable to an internal reference preparation ensuring metrological traceability of test results|
|Liquid for Ease-of-Use||Conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.|
|Negative Available||Complementary negative controls available offering a complete testing package.|
Randox | Blood Gas IQC & EQA
Depending on your symptoms, there may be some additional tests required to evaluate the complications of the virus. One of these tests is Blood Gases (or ABG). It is important to note that ABG tests are not done routinely in connection with Coronavirus and therefore cannot be used to diagnose COVID-19. This test should only be done in exceptional circumstances and on a case-by-case basis.
Randox Laboratories provide Blood Gas solutions of for both IQC and EQA. Visit our pages to find out more.
Randox Health | Consumer and Company Testing
The Randox Health Everyman, Everywoman and Signature packages now include an additional service that will test for COVID-19 and other respiratory viruses. Additionally, Randox can also supply a standalone COVID-19 test kit that includes an easy to use swab and return address. Results of this test will then be sent back to the user with the outcome of the test.
Randox is committed to saving and improving lives on a global scale, and will bring you updates on developments on our test for 2019-nCoV as and when they happen.